Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Callisto receives investment recommendation from independent European stock newsletter
May 18th, 2006
Callisto Pharmaceuticals, Inc., (KAL) a developer of new drug treatments in the fight against cancer and other major health threats, announced that Strong Buy Investor, an independent European online investment newsletter, recently spotlighted the company's promising investment potential, citing its research pipeline of new anticancer drug candidates and other competitive advantages. In its website report on Callisto, the Strong Buy Investor newsletter discussed the potential growth of shareholder value in the biotechnology sector, particularly involving companies with a promising research pipeline. "Oftentimes stock values have increased tenfold within years of a...
Source: Biotech Business Week (2006-05-18)
|
